Clinical Trial Update: Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial updates safety and efficacy of single-agent CC-5013 in relapsed and refractory multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• CC-5013 (lenalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED